Woogene B&G
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
WooGeneB&GCO supplies medicines and health products for livestock and companion animals, including antibiotics, nutritional supplements, disinfectants, microbial preparations, and vaccines, to distributors, direct corporate customers, and government agencies across South Korea.
It also produces active pharmaceutical ingredients for human use. Listed on KOSDAQ, Korea's tech and small-cap board, the company distributes through dealer networks, direct supply channels, and the Korea Public Procurement Service. A meaningful share of its revenue comes from exports, making international markets a significant part of its business alongside domestic sales.
Summary is AI-generated and may contain errors · figures from DART filings
WooGeneB&GCO has two subsidiaries, OSP and BowWow Korea, that operate in the premium pet food and companion-animal treat segments, broadening the group beyond its core veterinary pharmaceuticals business.
Woogene B&G in five facts
What does Woogene B&G do?
WooGeneB&GCO supplies medicines and health products for livestock and companion animals, including antibiotics, nutritional supplements, disinfectants, microbial preparations, and vaccines, to distributors, direct corporate customers, and government agencies across South Korea.
Where is Woogene B&G listed and in which sector?
Woogene B&G (Korean name: 우진비앤지) trades under KRX code 018620 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Woogene B&G?
Its market capitalisation was US$14M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Woogene B&G's latest annual revenue and operating profit?
For fiscal year 2025, Woogene B&G reported revenue of US$41.3M, operating profit of US$240.9K and a net loss of US$2.7M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 1.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 30
- Report on large shareholdings (5% rule) (standard)Sep 30
- Ex-rights (bonus issue)Capital raise · Jun 11
- Trading suspension (bonus issue)Capital raise · May 29
- Material event report (bonus issue)Capital raise · May 29
- [Amended] Share-pledge agreement that may change the largest shareholder
Woogene B&G's largest shareholder (Kang Jae-gu) pledged shares as loan collateral, securing up to US$1.83M.
Ownership change · May 20 - Trading suspension (share consolidation/split registration)M&A · Apr 23
- [Amended] Share-pledge agreement that may change the largest shareholderOwnership change · Jan 9